Yes, Medicare covers buprenorphine for opioid use disorder treatment through multiple pathways. Depending on how and where you receive the medication, coverage may come through Part B, Part D, or both. The out-of-pocket cost for generic versions can be as low as roughly $5 to $12 per month for those who qualify for low-income subsidies, though your actual costs depend on your specific plan.
How Part D Covers Buprenorphine Prescriptions
Medicare Part D prescription drug plans are required to cover buprenorphine products when they are medically necessary for treating opioid dependence. This includes both single-ingredient buprenorphine (formerly sold as Subutex) and combination buprenorphine-naloxone products (formerly sold as Suboxone). CMS mandates that Part D sponsors provide this coverage either by including the drug on their formulary or by granting an exception when a prescriber documents medical necessity.
Most Part D formularies now list generic buprenorphine-naloxone rather than the brand-name versions. Once generics became available, plans largely dropped brand-name Suboxone film from their formularies, which is typical Medicare practice across drug classes. If your plan only covers the generic and you need the brand for a medical reason, your prescriber can submit an exception request on your behalf.
Part D plans also have transition policies designed to prevent gaps in treatment. If you’re newly enrolled in a plan and your current buprenorphine product isn’t on the formulary, the plan must provide a temporary supply while you either switch to an equivalent covered medication or complete an exceptions process.
Part B Coverage Through Opioid Treatment Programs
Medicare Part B covers buprenorphine when you receive it through a Medicare-enrolled Opioid Treatment Program (OTP). This is a separate benefit from Part D and works differently. Instead of filling a prescription at a pharmacy, you receive your medication directly from the treatment program.
Medicare pays OTPs a bundled weekly rate that includes the medication itself plus counseling and therapy services. The bundled payment covers both oral buprenorphine (taken daily as a tablet or film) and injectable buprenorphine (administered no more than once every four weeks). Counseling within the bundle can be provided by social workers, licensed counselors, marriage and family therapists, addiction counselors, or certified peer specialists.
For patients who are stable enough to take medication at home rather than visiting the clinic daily, the OTP can also bill for take-home supplies of oral buprenorphine. These take-home supplies cover up to seven additional days at a time, with a maximum of one month’s worth of medication. This flexibility means you don’t necessarily need to visit the program every day once your treatment is established.
What You’ll Pay Out of Pocket
Your costs vary significantly depending on your plan, the specific product prescribed, and whether you qualify for financial assistance programs. Under Part D, generic buprenorphine-naloxone tablets have the lowest out-of-pocket costs. The monthly payer acquisition cost for generic tablets runs around $20 to $45, while your share depends on which formulary tier the drug sits on and your plan’s copay or coinsurance structure.
If you qualify for Medicare’s Extra Help program (the low-income subsidy), your copays drop substantially. In 2025, qualifying beneficiaries pay no more than $4.90 per prescription for generic buprenorphine or $12.15 for a brand-name version. Those amounts increase slightly in 2026 to $5.10 and $12.65.
For those without Extra Help, the coverage gap (sometimes called the “donut hole”) can still create a temporary cost spike during the year when your total drug spending hits a certain threshold. Once you pass through the gap and reach catastrophic coverage, your costs drop again.
Coverage for Pain vs. Opioid Use Disorder
Buprenorphine is FDA-approved for two distinct purposes: treating opioid use disorder and managing chronic pain. The formulation and cost differ dramatically depending on which condition it’s prescribed for, and this creates a real pricing gap for Medicare beneficiaries.
The opioid use disorder formulations (sublingual tablets and films) are far cheaper. Generic buprenorphine-naloxone tablets cost Medicare plans roughly $20 per month. Pain formulations like transdermal patches or buccal films cost dramatically more, with monthly payer costs ranging from $324 for generic patches to over $1,000 for brand-name buccal films. For patients, that translates to monthly out-of-pocket costs of $37 to $77 for pain formulations compared to $5 to $12 for the OUD versions. That’s a 6.6-fold difference at minimum between the least expensive options in each category.
Both types are coverable under Part D, but the cost difference is worth discussing with your prescriber if you use buprenorphine for pain management. Some clinicians have explored using the less expensive OUD formulations off-label for pain treatment, a practice already used in the VA health system.
Prescribing Rules and Access Protections
Federal law previously required physicians to obtain a special waiver (called an X-waiver) to prescribe buprenorphine for opioid use disorder. That requirement was eliminated in late 2022, which means any provider with a standard controlled substance license can now prescribe it. This change expanded the pool of Medicare-accepting providers who can write buprenorphine prescriptions.
CMS has also built in protections to ensure that opioid safety policies don’t accidentally block access to addiction treatment. Part D plans use automated systems to flag high opioid doses, but buprenorphine for opioid use disorder is specifically exempt from these safety edits. If a pharmacy claim is flagged for any reason, your prescriber only needs to confirm that the prescribed amount is intentional and medically necessary for the plan to approve it.
Your prescriber can also request a coverage determination in advance of writing the prescription, which can prevent delays at the pharmacy. This can be done on a standard or expedited timeline, depending on urgency.
Medicare Advantage Plans
If you have a Medicare Advantage plan (Part C), your buprenorphine coverage comes through the Part D drug benefit that’s typically bundled into your plan. The same CMS requirements apply: plans must cover buprenorphine for opioid use disorder and must offer transition supplies for new enrollees. However, the specific formulary tier, copay amounts, preferred pharmacies, and any prior authorization requirements can vary from one Advantage plan to another. Checking your plan’s formulary before filling a prescription, or asking your prescriber’s office to verify coverage, is the most reliable way to know your costs in advance.